Physician profile
Mark K Weeber
NPI 1144324492
$9,790.97
in general payments reported to CMS, 2019-2025
34 companies · $1,865 in 2025
The $1,865 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $953 · 2020: $1,223 · 2021: $1,214 · 2022: $1,869 · 2023: $920 · 2024: $1,747 · 2025: $1,865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,513 · Education: $18.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,512.77 |
| Education | $18.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,173.72 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Amgen INC. | $1,265.85 | 2019-2025 | Evenity, Prolia, Otezla |
| Pfizer INC. | $962.54 | 2019-2025 | |
| Novo Nordisk INC | $506.99 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $399.49 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $379.53 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $329.08 | 2019-2025 | Airsupra, Breztri |
| Allergan, INC. | $306.86 | 2019-2020 | |
| Daiichi Sankyo INC. | $296.10 | 2019-2025 | Injectafer |
| Amarin Pharma, INC. | $261.47 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.63 | 2019-2025 | Jardiance, Ofev |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $208.95 | 2021-2022 | |
| Eisai INC. | $204.10 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $156.34 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Dexcom, INC. | $150.66 | 2024-2025 | Dexcom G6 Transmitter |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $127.81 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astellas Pharma US INC | $101.01 | 2019-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $97.70 | 2019-2023 | |
| Exact Sciences Corporation | $94.13 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $75.71 | 2021-2024 | Proclaim, Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $58.11 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $54.37 | 2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $52.56 | 2025 | Rexulti |
| Aimmune Therapeutics, INC. | $48.66 | 2025 | Zenpep |
| Esperion Therapeutics, INC. | $41.74 | 2020-2021 | |
| Sanofi Pasteur INC. | $35.11 | 2023-2024 | |
| Vertex Pharmaceuticals Incorporated | $27.29 | 2025 | |
| Biodelivery Sciences International, INC. | $24.31 | 2019-2020 | |
| Optinose US, INC. | $23.48 | 2024 | |
| Collegium Pharmaceutical, INC. | $19.45 | 2023 | Xtampza |
| Regeneron Healthcare Solutions, INC. | $18.99 | 2023 | Evkeeza |
| Phathom Pharmaceuticals, INC. | $17.58 | 2025 | Voquezna |
| Tandem Diabetes Care, INC. | $14.80 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Janssen Pharmaceuticals, INC | $11.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Weeber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.